Overcoming sociodemographic factors in the care of testicular cancer patients at a safety net hospital.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 398-398
Author(s):  
Nathan Chertack ◽  
Rashed Ghandour ◽  
Nirmish Singla ◽  
Yuval N. Freifeld ◽  
Ryan C. Hutchinson ◽  
...  

398 Background: Optimal treatment of GCT in underserved populations is subject to barriers that are associated with worse clinical outcomes. We determine whether standardized treatment of GCT can overcome such sociodemographic factors limiting patient care. Methods: The records of all patients undergoing primary treatment for GCT were analyzed from both a public safety net hospital and an academic tertiary care center in the same metropolitan area. Patients at both institutions were managed by the same group of physicians in the context of multidisciplinary cancer care. Patients were grouped by care center and clinicopathologic features, practice patterns, and outcomes were analyzed. Results: 106 and 95 patients underwent initial treatment for GCT between 2006 and 2018 in the safety net hospital and tertiary care center, respectively. Safety net patients were younger (29 vs 33 years, p=0.005), more likely to be Hispanic (79% vs 11%), more likely to be uninsured (80% vs 12%, p<0.001), and present via the emergency department (76% vs 8%, p<0.001). They were more likely to have metastatic (stage II/III) disease (42% vs 26%, p=0.025). On multivariable analysis, presence of lymphovascular invasion (OR=0.30, p=0.008) and embryonal carcinoma component (OR=0.36, p=0.02) were associated with surveillance vs adjuvant treatment for Stage I patients; hospital setting was not (OR=0.67, p=0.55). For patients with Stage II/III NSGCT, there was no difference in performance of PC-RPLND at the safety net hospital vs tertiary care center (52% vs 64%, p=0.53). No difference in recurrence rates between cohorts (5% vs 6%, p=0.76) was observed. Conclusions: Sociodemographic factors are often associated with adverse clinical outcomes in the treatment of GCT; this may be overcome with integrated, standardized management of testicular cancer.

Cancer ◽  
2020 ◽  
Vol 126 (19) ◽  
pp. 4362-4370
Author(s):  
Nathan Chertack ◽  
Rashed A. Ghandour ◽  
Nirmish Singla ◽  
Yuval Freifeld ◽  
Ryan C. Hutchinson ◽  
...  

2016 ◽  
Vol 7 (3) ◽  
pp. 345-353 ◽  
Author(s):  
Vishwas D. Pai ◽  
Sudhir Jatal ◽  
Vikas Ostwal ◽  
Reena Engineer ◽  
Supreeta Arya ◽  
...  

2021 ◽  
Vol 34 (2) ◽  
pp. 229-231
Author(s):  
Thomas Woodard ◽  
Lueke Anderson ◽  
Jessica Ehrig ◽  
Courtney Shaver ◽  
Michael Hofkamp

2021 ◽  
Vol 12 ◽  
Author(s):  
Vasudha Mantravadi ◽  
Jeffrey J. Bednarski ◽  
Michelle A. Ritter ◽  
Hongjie Gu ◽  
Ana L. Kolicheski ◽  
...  

The implementation of severe combined immunodeficiency (SCID) newborn screening has played a pivotal role in identifying these patients early in life as well as detecting various milder forms of T cell lymphopenia (TCL). In this study we reviewed the diagnostic and clinical outcomes, and interesting immunology findings of term infants referred to a tertiary care center with abnormal newborn SCID screens over a 6-year period. Key findings included a 33% incidence of non-SCID TCL including infants with novel variants in FOXN1, TBX1, MYSM1, POLD1, and CD3E; 57% positivity rate of newborn SCID screening among infants with DiGeorge syndrome; and earlier diagnosis and improved transplant outcomes for SCID in infants diagnosed after compared to before implementation of routine screening. Our study is unique in terms of the extensive laboratory workup of abnormal SCID screens including lymphocyte subsets, measurement of thymic output (TREC and CD4TE), and lymphocyte proliferation to mitogens in nearly all infants. These data allowed us to observe a stronger positive correlation of the absolute CD3 count with CD4RTE than with TREC copies, and a weak positive correlation between CD4RTE and TREC copies. Finally, we did not observe a correlation between risk of TCL and history of prenatal or perinatal complications or low birth weight. Our study demonstrated SCID newborn screening improves disease outcomes, particularly in typical SCID, and allows early detection and discovery of novel variants of certain TCL-associated genetic conditions.


IJID Regions ◽  
2021 ◽  
Author(s):  
Suvaporn Anugulruengkitt ◽  
Sirinya Teeraananchai ◽  
Napaporn Chantasrisawad ◽  
Pathariya Promsena ◽  
Watsamon Jantarabenjakul ◽  
...  

2021 ◽  
Vol 2 (1) ◽  
pp. 20-26
Author(s):  
Kerem Sami Kaya ◽  
İbrahim Yağcı ◽  
Uğur Doğan ◽  
Nurullah Seyhun ◽  
Suat Turgut

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Michael G Silverman ◽  
Molly H O’Brien ◽  
Kathleen R Avery ◽  
Annmarie Chase ◽  
Carol D Pierce ◽  
...  

Background: The concurrent use of therapeutic hypothermia (TH) following cardiac arrest and mechanical circulatory support (MCS) for cardiogenic shock is becoming increasingly common. Little is known however, about the combined use of TH and MCS for patients after ROSC following a cardiac arrest who remain in cardiogenic shock. Therefore we describe the experience with concomitant use of TH and MCS from a large academic tertiary care center in Boston. Methods: Baseline characteristics and clinical outcomes at hospital discharge were reported for patients undergoing TH following cardiac arrest who also received MCS for cardiogenic shock. MCS included Intra-aortic balloon pump (IABP) two percutaneous ventricular assist devices (Impella, and TandemHeart), and extracorporeal membrane oxygenation (ECMO). Clinical outcomes included mortality as well as cerebral performance category (CPC) at hospital discharge. Results: There were a total of 14 patients who underwent concomitant TH and MCS following a cardiac arrest. Baseline characteristics and clinical outcomes are noted in the Figure. 9 patients underwent placement of IABP, 2 patients an Impella pump, 2 patients a TandemHeart, and 1 patient ECMO. All 14 cardiac arrests were due to cardiovascular etiologies; 9 of 14 had STEMI. 9 of 14 patients had an initial shockable rhythm. Mean age was 56 years (+/- 19), mean downtime was 35 minutes (+/- 24). All patients were vasopressor dependent. Bleeding events are noted in the table. 8 patients survived to hospital discharge, all with good neurologic outcome. These rates were comparable to the survival rates and neurologic outcomes among 82 patients who underwent TH post cardiac arrest (from cardiovascular etiologies) without concomitant MCS (Figure). Conclusion: Based on our experience from a large academic tertiary care center, concomitant use of TH and MCS is both safe and feasible with an encouraging rate of cardiac and neurologic recovery.


Sign in / Sign up

Export Citation Format

Share Document